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Abstract Background: Some patients with chronic hepatitis C virus (HCV) infection
forego treatment due to concerns about treatment efficacy, treatment dura-
tion, and side effects.
Objective: The purpose of this study was to quantify patient preferences
among possible outcomes associated with new, direct-acting antiviral agents
(DAAs) for the treatment of HCV infection and determine which treatment
features are most important to patients in making treatment decisions.
Methods:Adult participants with a self-reported physician diagnosis of HCV
infection in five countries completed a web-enabled, choice-format conjoint
analysis survey. The survey presented participants with 20 treatment-choice
questions. Each treatment-choice question included a pair of hypothetical
treatment profiles with varying levels of six attributes: treatment duration;
chance of getting rid of the virus completely (i.e. likelihood of a sustained
virologic response [SVR]); weeks on an additional, third medicine (i.e. a
DAA); risk of a severe rash; risk of severe anemia; and number of times a day
the third medicine is taken. Treatment-choice questions were based on a pre-
determined experimental design with known statistical properties. Random-
parameters logit was used to estimate preference weights for all attribute
levels and the mean relative importance of each attribute.
Results: 284 participants completed the survey. Likelihood of an SVRwas the
most important outcome to participants, followed by severe anemia risk,
severe rash risk, therapy type (a combination of total weeks of treatment and
weeks on the third medicine), and dosing of the third medicine. Controlling
for other factors, preferences were similar across all therapy types examined.
Conclusion: Patients with HCV infection indicate a willingness to accept an
increased risk of side effects for sufficient improvement in the likelihood of
treatment response.
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Key points for decision makers
 An understanding of how patients with hepatitis C virus (HCV) infection view the benefits and
risks of new therapies is necessary for treatment planning at both the patient and the public
health levels
 HCV patients surveyed indicated that the chance of getting rid of the virus completely
(i.e. likelihood of a sustained virologic response [SVR]) was the most important determinant of
treatment choice, and patients were willing to accept the additional side effects associated
with newer therapies for sufficient improvements in SVR
 Duration of treatment had little impact on stated treatment choices
Introduction
Chronic hepatitis C virus (HCV) infection dam-
ages the liver and, over time, can cause cirrhosis,
liver failure, and liver cancer. Not all patients with
HCV infection will experience these severe mani-
festations,[1] but the majority of patients will exhibit
some degree of liver damage upon diagnosis due to
the slow, asymptomatic progression of the dis-
ease.[2] Treatment generally is recommended for
patients with significant liver fibrosis and often of-
fered to patients in earlier stages of liver disease.
For a number of years, the standard of care for
the treatment of chronic HCV infection has been
combination therapy with pegylated interferon
(peginterferon) plus ribavirin.[2,3] For patients in-
fected with genotype 1 virus, combination anti-
viral therapy is effective in producing a sustained
virologic response (SVR) in about half of those
initiating treatment. Rates of SVR have improved
over time, as therapy has evolved frommonotherapy
and combinations that included the non-pegylated
form of interferon.[2] Despite improvements in
treatment effectiveness, the number of patients
seeking therapy for chronic HCV infection has
not increased over time, and evidence suggests
that only a small percentage of patients – some-
times as few as 6% – receive antiviral therapy.[4-6]
Commonly cited reasons for low rates of treat-
ment among chronically infected individuals in-
clude contraindications to therapy,[5,7] the slowly
progressive nature of the disease,[8,9] low treat-
ment efficacy,[8,9] and treatment burden including
treatment duration,[5] side effects,[8,9] and cost.[8]
Treatment with new and emerging, direct-acting
antiviral agents (DAAs) for HCV may offer im-
proved rates of SVR (and, for some patients,
reduced treatment duration), but they are not
without additional side effects, cost, and other
potential complications, such as the development
of drug resistance.[10] Furthermore, these new
treatments are administered alongside peginterferon
and ribavirin, potentially compounding patients’
concerns about the burden of treatment.
While some evidence of patient preferences
regarding HCV treatments exists,[11,12] the avail-
able literature focuses on treatment with ribavirin
plus interferon or peginterferon. In this paper,
we report the results of a choice-format conjoint
analysis survey that asked patients to choose
among alternative, hypothetical HCV treatments
that include characteristics of new DAAs. Each
hypothetical treatment in the survey varied by
treatment effectiveness, duration, risk of side ef-
fects, and additional pill burden associated with
DAAs.
Choice-format conjoint analysis is a system-
atic method of eliciting trade-offs to quantify the
relative importance participants assign to various
treatment attributes or outcomes. It is based on
the premise that medical interventions are com-
posed of a set of attributes or outcomes and that
the attractiveness of a particular intervention to
an individual is a function of these attributes.[13,14]
Conjoint techniques are grounded in both psy-
chology and economic theory[15,16] and offer several
advantages over simple rating or ranking exercises,
including the ability to examine the strength of in-
dividual preferences across treatment attributes and
observe the willingness to trade between different
attributes.[14,17] While the treatment combinations
presented in our survey are hypothetical in nature,
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the specific features of the treatments reflect the




A choice-format conjoint survey instrument
was constructed to reflect key aspects of HCV
treatment with the current standard of care, with
or without DAAs (see the Supplemental Digital
Content (SDC), http://links.adisonline.com/PBZ/
A40). Standard of care was described as an in-
jection with a pen once a week (peginterferon) and a
tablet twice a day (ribavirin) for 48 weeks;[2,3] the
third drug representing the DAA was assumed to
be administered orally. Relevant treatment fea-
tures and levels were chosen based on an informal
review of relevant literature (including package
inserts and online sources of information about
HCV treatment), consultation with clinical ex-
perts, the authors’ previous experience conduct-
ing choice studies in HCV, and face-to-face in-
terviews with HCV-infected patients. Six treat-
ment attributes were determined from this process
(table I): total number of weeks on treatment;
chance of getting rid of the virus completely (i.e.
chance of an SVR, defined as the absence of
plasma HCV ribonucleic acid [RNA] 6 months
after therapy completion[2,3]); number of weeks the
third medicine is taken; chance of a treatment-
limiting severe rash; chance of severe anemia; and
the number of times a day the third medicine is
taken.
A number and range of levels were assigned to
each treatment attribute. Greater numbers of lev-
els allow for the estimation of non-linear prefer-
ences within attributes. However, because the
sample size requirements increase exponentially
with the number of levels included for each at-
tribute, the number of levels generally was limited
to three with the exception of the duration at-
tributes ‘total number of weeks on treatment’ and
‘number of weeks the third medicine is taken.’
The duration attributes were combined to create
Table I. Attributes and levels for the treatment-choice questions
Attribute labels Abbreviated label Levels
Total number of weeks on treatmenta Total weeks 24 weeks
28 weeks
48 weeks
Chance that the treatment will get rid of the
virus completely
Chance of getting rid of virus completely 85 out of 100 (85%)
70 out of 100 (70%)
45 out of 100 (45%)
Number of weeks the third medicine is takena No. weeks on 3rd medicine 0 weeks (no third medicine)b
12 weeks
24 weeks (with 4-week lead-in)
44 weeks (with 4-week lead-in)
Chance of getting a severe rash that requires
stopping the third medicine
Chance of severe rash No chance of severe rash (0%)b
5 out of 100 (5%)
12 out of 100 (12%)
Chance of getting severe anemia that requires
additional injections of a fourth medicine while
taking the third medicine
Chance of severe anemia No chance of severe anemia (0%)b
20 out of 100 (20%)
70 out of 100 (70%)
Number of times a day the third medicine is taken No. times/day the 3rd medicine is taken No additional tabletb
3 tablets every 12 hours (2 times/day)
2 tablets every 8 hours (3 times/day)
4 tablets 3 times a day
a The levels of the ‘total number of weeks on treatment’ and ‘number of weeks the third medicine is taken’ attributes were constrained to
reflect five hypothetical treatments of interest, as shown in table II.
b These attribute levels occur together whenever the treatment does not include a third drug.
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five therapy options reflecting both the current
standard of care and the probable treatment pat-
terns with DAAs (table II). The levels assigned to
dosing frequency and SVR chance similarly were
chosen to represent realistic treatment options.
Upper ranges of probabilities for the side effect
attributes were roughly based on clinical trial
reports but also designed to be large enough to in-
duce respondents to refuse an otherwise accept-
able treatment profile. Levels for the side effect
and dosing attributes were set to ‘no chancey’
and ‘no additional tablet,’ respectively, when the
treatment option presented reflected the current
standard of care (see, for example, treatment A in
figure 1).
Task Construction and Experimental Design
Attributes and levels were combined to create
pairs of hypothetical treatment profiles. Survey
participants were asked to indicate which hypo-
thetical treatment in each pair they would choose
if the two treatments shown were the only options
available. An example treatment-choice question
is shown in figure 1. Participants answered 20
treatment-choice questions (figure 1) from among
the constructed treatment profiles.
To create treatment profiles for the choice
questions, we employed a commonly used D-
efficiency algorithm.[18-20] Side effect chances were
constrained to zero when no third medicine was
included in a choice task. This reduces the orthogo-
nality and efficiency of the design but is necessary
to allow estimation of preferences across treat-
ments, independent of the other attributes in the
survey. This process produced a statistically effi-
cient experimental design resulting in 72 choice
pairs, eight survey versions with nine treatment-
choice questions each. The order of the nine ques-
tions was randomized, and the choice pair ap-
pearing in question three was repeated as question
ten as an internal validity test. The final experimen-
tal design consisted of eight survey versions, each
containing ten treatment-choice questions. Each
participant was randomly assigned to two of the
eight versions.
Instrument Design and Pre-Testing
Prior to answering the treatment-choice ques-
tions, participants viewed descriptions of the at-
tributes and levels, including a graphic tutorial to
communicate risk.[21] Participants were reminded
that all treatments included peginterferon plus
ribavirin and told to assume that any side effects
of these drugs, such as flu-like symptoms, fatigue,
and depression, were the same for each treatment.
Participants were informed that any side effects
shown in the treatment-choice questions were
only for the third drug and would resolve upon
discontinuation. Participants also were asked to
assume that all medical bills, including the cost of
medicines, were covered by health insurance.
Standard demographic information (e.g. age,
gender, marital status, and education) and ques-
tions about participants’ experiences with HCV
infection and treatment were included in the survey.
The survey was pre-tested through a series of
one-on-one, face-to-face interviews conducted in
the UK and the US. During the interviews, par-
ticipants were asked to read the survey out loud
and think aloud as they answered the survey
questions. Two members of the study team re-
corded answers to all questions and noted any
difficulties understanding any of the information
presented, including the choice tasks. Addition-
ally, the study team queried participants to un-
derstand how the attributes and levels affected
Table II. Hypothetical treatments of interest
Treatment Total number of weeks on treatmenta Number of weeks the third medicine is taken
A 24 weeks 12 weeks
B 28 weeks 12 weeks
C (standard of care) 48 weeks 0 weeks (no third medicine)
D 48 weeks 24 weeks (with 4-week standard-of-care lead-in)
E 48 weeks 44 weeks (with 4-week standard-of-care lead-in)
a Pegylated interferon plus ribavirin are taken for the entire duration of treatment.
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participants’ decision making. This process was
used to identify attributes that did not influence
treatment choice (e.g. risk of jaundice) and con-
firm ranges for the levels of probabilistic attrib-
utes, as described in the Survey Instrument section.
The pre-test sample in the UK consisted of eight
individuals who self-reported current or previous
treatment for chronic HCV infection. The US
sample (n = 7) included both treatment-naı¨ve and
treatment-experienced patients of the Adult Liver
Clinic at the University of Florida (UF).
The study was approved by the UF Institu-
tional Review Board (Gainesville, FL, USA) and
Research Triangle Institute (RTI) International’s
Office of Research Protection and Ethics (Re-
search Triangle Park, NC, USA). All survey
participants were required to provide informed
consent.
Treatment Features
Total number of weeks
on treatment
48 weeks (about 1 year) 28 weeks (about 7 months)
12 weeks
(from the start to week 12)
No third medicine
No chance of severe rash
No chance of severe anemia No chance of severe anemia
No additional tablet
2 tablets every 8 hours
















treatment will get rid of
the virus completely
Number of weeks the
third medicine is taken
Chance of getting






injections of a fourth
medicine while taking
the third medicine
Number of times a day
the third medicine
is taken
Treatment A Treatment B
Which treatment
would you choose
if these were your
only options?
Treatment A Treatment B
Fig. 1. An example treatment-choice question. In the survey, different colors were used to represent different likelihoods of chance events
(see the Supplemental Digital Content, http://links.adisonline.com/PBZ/A40, for further information).
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Data Collection
Survey participants were required to have a
self-reported physician diagnosis of HCV infec-
tion and be at least 18 years of age. Knowledge
Networks (KN), a company that specializes in
survey research using online surveys, recruited
participants in five countries – the UK, France,
Germany, Spain, and the US – from two well
established online patient panels. Panel members
‘opt in’ to the panels and agree to participate in
online surveys without remuneration.
Email invitations were sent to panel members
who previously reported a diagnosis of HCV in-
fection in a comprehensive health condition ques-
tionnaire. Panel members who had not completed
the health condition questionnaire were invited
and screened for a self-reported physician diag-
nosis of HCV infection. Potential participants
from the general population enrolled in other KN
consumer panels were screened to complete the
sample.KNadministered theweb-enabled survey in
November 2010.
Statistical Analysis
Summary statistics were calculated for demo-
graphic, disease, and treatment history variables
for all participants. An internal stability test as
described in the Task Construction and Experi-
mental Design section was conducted for all re-
spondents. Multivariate analyses were conducted
on samples excluding and including participants
who ‘failed’ the stability test. Respondent choices
also were examined for dominance. For the pur-
poses of this study, dominance was defined as
choosing the treatment option with the better
level of a specific attribute on at least 15 of the 20
choice questions. Because some individuals may
have very strong preferences over a specific treat-
ment attribute, there was no plan to exclude those
who dominated from the multivariate analysis.[22]
However, individuals who showed no variation
in their responses – that is, they always chose
treatment A or treatment B – were excluded.
Multivariate random-parameters logit was
used to estimate the effect of each treatment at-
tribute on the probability of choosing a treat-
ment. Random-parameters logit is a limited de-
pendent-variable estimator in which the dependent
variable is treatment choice and the independent
variables are the levels of each attribute included
in the survey. This estimation method controls
for within-participant correlation and avoids po-
tential estimation bias from unobserved preference
weight heterogeneity by estimating a distribution
of preference weights across participants for each
treatment attribute.[23,24] Heterogeneity of pref-
erences within attribute levels was assessed using
t-statistics.
The parameter estimates from the logit model
can be interpreted as mean preference weights or
as log-odds ratios, indicating the relative strength
of preference for each attribute level.[25] The dis-
tance between parameter estimates for the best
and worst levels of an attribute can be interpreted
as the overall relative importance of the attribute
over the specific ranges presented in the survey.
For example, the importance of SVR was esti-
mated as the importance of increasing chance of
SVR from 45% to 85%. Relative importance scores
are calculated by assigning a value of ten to themost
important attribute and scaling the importance
weights for the remaining attributes comparatively.
The relative importance scores are a subset of
the preference weights. The preference weights,
calculated as log-odds ratios from the parameter
estimates, indicate the strength of preference for
each attribute level. The distance between pref-
erence weights for the best and worst level within
an attribute yields the relative importance of that
attribute overall. We report both derivations be-
cause the preference weights provide information
about the attributes and the levels. The relative
importance scores only provide information
about each attribute as a whole (again, over the
range of levels examined in the survey).
All treatment attributes were modeled as ran-
dom, effects-coded categorical variables with Nor-
mal distributions.[13,26] A dummy variable was
used to represent standard of care, which always
appeared in the choice tasks with no chance of
severe rash or severe anemia. The other four thera-
pies shown in table II were modeled as a categorical
variable. Therefore, the results are interpreted as the
relative importance of each therapy and treatment
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Email invitations were sent to 4936 respon-
dents with self-reported HCV-infection (UK =
483; France = 1729; Germany = 655; Spain = 424;
US = 1645). Initial response rates across the five
countries varied from 10% to 47% (UK = 35%;
France= 37%; Germany= 38%; Spain= 47%; US=
10%). Among those initially responding to the
email invitation, 284 participants met the in-
clusion criteria and completed the survey (UK =
56; France= 56;Germany= 58; Spain= 58;US= 56).
The majority of participants were male (53%),
employed (63%), and had at least a 4-year college
education (53%). Forty-nine percent of partic-
ipants were married, and 26% were single. The
mean age of the participants was 42 (standard de-
viation [SD] 12) years.
Participants’ disease and treatment experi-
ences and other characteristics are summarized in
table III. All participants except those residing in
Spain answered the disease and treatment expe-
rience questions. The majority of the remaining
participants (62%) were diagnosed with HCV
infection 2 or more years prior to completing the
survey. With respect to treatment experience,
approximately 27% were treatment naı¨ve, 21%
were on treatment for the first time, 33% were
not currently on treatment but had been treated
in the past, and 20% were currently on treatment
and also had been treated in the past. Among
participants who were untreated or waited before
seeking treatment, most reported delayed treat-
ment because they did not realize that hepatitis
was serious, their doctors told them that treat-
ment was not yet required, or they were worried
about the side effects of treatment.
Fewer than 3% of participants dominated on a
particular treatment attribute: one dominated
on SVR, one on the number of weeks the third
medicine was taken, two each on risk of severe
anemia and severe rash, and one on the number
of times per day the third medicine was taken.
These seven individuals’ observations were included
in the regression analysis. Eight participants who
selected the same treatment option across all the
treatment-choice questions presented were ex-
cluded from the sample. The final sample size
used to estimate HCV treatment preferences was
276. Results from the random-parameters logit
regression model and the SDs for each parameter
distribution are given in table IV. These results
include data from 79 respondents who failed the
stability test; model results with and without
these data were not statistically different. Results
also did not differ between treatment-naı¨ve and
-experienced patients.
Preference Weights
Figure 2 shows the preference weight log-odds
ratios relative to the mean attribute effect nor-
malized at zero. The vertical bars around each
parameter indicate the 95% confidence interval
(CI) for the estimate. The estimated preference
weights for the effects-coded attributes were con-
sistent with the natural ordering of the categories;
that is, better clinical outcomes were preferred to
worse clinical outcomes.
The vertical distance between adjacent prefer-
ence weights indicates the relative importance of
moving from one level of an attribute to an ad-
jacent level of that attribute. For example, the
relative importance of an improvement in the
chance of severe rash from 5% to 0% is approx-
imately 0.24. Similarly, the relative importance of
an improvement in the chance of SVR from 70% to
85% is approximately 0.77. Therefore, the impor-
tance of an improvement from 70% to 85% chance
of SVR is 3.1 times as important as an improvement
from 5% to 0% in the chance of severe rash.
Relative Importance Scores
The distance between preference weights for
the best and worst levels of an attribute can be
interpreted as the overall relative importance of
the attribute over the specific ranges presented in
the survey. Figure 3 presents the mean relative
importance scores (and 95% CIs) for the attrib-
utes included in the survey. The absolute scale of
the relative importance scores is arbitrary; only
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Table III. Demographics, disease, and treatment historya
Characteristic Category n (%)b
Demographics (n= 284)
Gender Male 150 (52.8)
Female 134 (47.2)
Marital status Married 140 (49.3)
Widowed 7 (2.5)
Divorced or separated 45 (15.8)
Single 74 (26.1)
Other 18 (6.3)
Age, y [mean (SD)] 41.6 (11.9)
Highest level of education Secondary school qualification or less 129 (45.4)
University first degree 86 (30.3)
Some postgraduate education but no higher degree obtained 22 (7.7)
Postgraduate or professional qualification 42 (14.8)
Other 5 (1.8)
Employment Employed (full-time/part-time/self) 178 (62.7)
Student/retired/other 38 (13.4)
Unable to work 41 (14.4)
Unemployed 27 (9.5)
Disease and treatment history (n= 226)c
How long ago were you diagnosed with
hepatitis C?
Less than 6mo 16 (7.1)
6mo to 1 y 34 (15.0)
2–5 y 67 (29.7)
6–10 y 46 (20.4)
More than 10 y 63 (27.9)
Treatment experience summary Treatment naı¨ve 61 (27.0)
On treatment for the first time 47 (20.8)
Not currently on treatment but treated in the past 74 (32.7)
Currently on treatment and treated in the past 44 (19.5)
Why didn’t you start treatment for your
hepatitis C right away?d
I didn’t realize that hepatitis C was serious 13 (19.7)
My doctor said I didn’t need treatment because my liver was okay 13 (19.7)
I was worried about the side effects 15 (22.7)
I didn’t think the medicine would work for me 5 (7.6)
I thought better treatment might be available in the future 8 (12.1)
The medicines were too expensive 5 (7.6)
I didn’t want my friends, loved ones, or co-workers to know I had hepatitis C 6 (9.1)
I was afraid that the medicines for hepatitis C would interact with medicines I was
taking for another condition
6 (9.1)
My doctor said that treatments for hepatitis C were not a good idea for people like me 1 (1.5)
I couldn’t fit the treatment into my life at the time 9 (13.6)
Other 16 (24.2)
a Proportions may not sum to 100 due to rounding.
b Unless otherwise stated.
c Participants in Spain (n =58) were not asked any disease or treatment history questions due to ethical restrictions.
d Participants could select more than one category.
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relative differences among attribute levels are
meaningful. Given the range of levels of each at-
tribute in the study, chance of SVR is the most
important attribute for HCV-infected patients
participating in the survey, followed by chance of
severe anemia and chance of severe rash. The
importance of changes in treatment type and the
number of times per day the third medicine is taken
was not statistically significant. Even though
mean relative importance differed among all at-
tributes, these differences are not always statisti-
cally significant. For example, SVR is statistically
significantly more important than the other four
attributes (p< 0.05). Also, SVR is 1.7 times as im-
portant as chance of severe anemia and 5.9 times as
important as chance of severe rash (p< 0.05).
Discussion
While the rate of new HCV infection in the US
and Europe declined dramatically following the
development and implantation of blood screening
in 1992,[3] the burden of chronic HCV infection is
expected to increase through the year 2020 and
beyond as the patient population ages and their
disease progresses.[27-30] In the absence of new
treatments that would reverse liver damage, the
primary intervention that could effectively reduce
the health impact of HCV infection in the US is
antiviral therapy. Davis et al.[28] estimated that
the risk of liver-related death could be reduced by
36% with current peginterferon-based therapy,
but only if all infected patients were treated.
Since a universal treatment strategy is not
feasible, the primary hope for reducing the burden
of HCV and its complications lies in improving the
effectiveness of therapy. However, even highly
effective therapies will be unsuccessful if patients
are not willing to take them. Treatment providers
must understand patients’ subjective assessments
of the benefits, risks, and burden of therapy if newly
emerging treatments such as protease inhibitors and
Table IV. Regression results
Variablea,b Mean estimates: random parameters in utility
function
SDs of parameter distributions
Coefficient SE t-Statistic p-Value Coefficient SE t-Statistic p-Valuec
Treatment A 0.03 0.03 0.78 0.43 0.07 0.04 1.84 0.07
Treatment B 0.02 0.03 0.56 0.58 0.07 0.04 1.62 0.10
Treatment C 0.09 0.12 0.70 0.48 0.18 0.17 1.07 0.29
Treatment D 0.00 0.03 -0.03 0.98 0.01 0.04 0.17 0.87
Treatment E -0.05 0.09 -0.53 0.60 -0.14 0.19 -0.74 0.46
85% chance of getting rid of virus completely 0.92 0.05 18.15 0.00 0.98 0.05 19.02 0.00
70% chance of getting rid of virus completely 0.15 0.03 5.22 0.00 0.09 0.06 1.53 0.13
45% chance of getting rid of virus completely -1.07 0.05 -20.18 0.00 -1.07 0.08 -13.45 0.00
No chance of severe rash 0.19 0.03 5.89 0.00 0.11 0.04 2.62 0.01
5% chance of severe rash -0.05 0.03 -1.47 0.14 0.02 0.04 0.45 0.66
12% chance of severe rash -0.14 0.03 -4.50 0.00 -0.13 0.06 -1.99 0.05
No chance of severe anemia 0.60 0.05 12.05 0.00 0.73 0.06 12.14 0.00
20% chance of severe anemia 0.00 0.03 0.01 0.99 0.07 0.06 1.23 0.22
70% chance of severe anemia -0.60 0.05 -11.99 0.00 -0.81 0.09 -8.81 0.00
3 tablets every 12 hours 0.01 0.03 0.44 0.66 0.03 0.05 0.52 0.60
2 tablets every 8 hours 0.02 0.03 0.49 0.62 0.01 0.05 0.23 0.82
4 tablets 3 times a day -0.03 0.03 -0.93 0.35 -0.04 0.07 -0.53 0.60
a The omitted category is the worst level. The categorical variables were effects coded (1, 0, -1), which means that the omitted category was
the negative sum of the other variables. All parameters were Normally distributed.
b See table II for definitions of treatments A–E.
c p-Values below 0.05 indicate heterogeneous preferences for the attribute level.
SD = standard deviation; SE = standard error.
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other DAAs are to measurably impact projected
trends in HCV-related liver disease. Yet, existing
evidence suggests that providers underestimate
the relative importance of side effects and other
aspects of HCV treatment to patients.[7,31,32] To
our knowledge, this is the first quantitative as-
sessment of patients’ preferences for the likely
features of what may soon become the dominant
treatment for chronic HCV infection: peginterferon
plus ribavirin plus a DAA.
The results from this survey provide important
information that may guide decision making and
promote patient-centered care.[33] First, while the
patients in our survey are concerned about addi-
tional side effects associated with the addition of
DAAs to treatment, they are willing to accept
these risks in exchange for improvements in the
likelihood of successful treatment. Second, the ab-
sence of a ranking in preferences across the four
hypothetical therapies, controlling for standard
of care, suggests that patients are less concerned
with duration per se than they are with other as-
pects of treatment. That is, patients are willing
to accept additional weeks of therapy for a suf-
ficient improvement in treatment effectiveness.
Conversely, reductions in treatment duration
alone may not induce patients to begin therapy,
presenting a challenge to improving HCV treat-
ment rates.
One reason for the relative unimportance of
treatment duration in this study may be the rela-
tively high importance of SVR. Fraenkel and
colleagues[12] found that HCV-infected patients
who perceived higher benefits of treatment were
much more willing to accept treatment-related
side effects. Similarly, Hauber and colleagues[11]
found that increases in the rate of SVRwere more
than twice as important to patients as avoiding
days with flu-like symptoms. There also is evi-
dence that achieving SVR has a significant and
independent impact on patients’ health-related
quality of life during treatment.[34]










































































Fig. 2. Treatment attribute preference weights (n = 276). The vertical bars denote the 95% confidence interval around the point estimate.
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A second possible reason why participants in
this study may be relatively unconcerned about
reductions in treatment duration is ‘duration ne-
glect.’[35-38] Duration neglect is a phenomenon
observed in empirical research where people tend
to ignore or under-weight duration when making
decisions. In related research, researchers have
identified an additive duration effect in which
people appear to care about duration, but the
effect of duration on decision making is weak and
does not depend on the intensity of the experience
over a given duration.[39] In the current study, par-
ticipants appeared to ignore or under-weight dura-
tion, even though longer durations are associated
with the potentially troublesome side effects of
standard of care. This is particularly surprising
given the fact that a large majority of participants
in this study were treatment experienced and that
patients were reminded of the side effects asso-
ciated with standard of care in the survey. How-
ever, the conclusion that patients do not value
decreases in duration independently from other
treatment attributes, though counter-intuitive, is
consistent with empirical findings in the psy-
chology and economics literatures.
The results presented here are best interpreted
with an awareness of several issues and qualifica-
tions. First, while choice-format conjoint analysis
methods are increasingly used to support post-
marketing regulatory decisions, identify optimal
treatment guidelines, and promote patient-centered
medicine,[14,40,41] they have limitations. The most
important limitation is that participants evaluate
hypothetical treatments. These trade-offs are in-
tended to simulate possible clinical decisions but
obviously do not have the clinical consequences
of actual decisions. Thus, differences may arise
between stated and actual choices. Empirical
examination of the correspondence between stated
and revealed preferences in healthcare is encour-
aging, but limited, to our knowledge, to a single
study examining physicians’ alcoholism med-
ication prescribing decisions.[42]
In this study, an attempt was made to minimize
such potential differences by offering alternatives
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Fig. 3. Treatment attribute mean relative importance scores (n =276). The vertical bars denote the 95% confidence interval around the point
estimate.
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possible, with the exception that participants were
presented with a forced-choice response (i.e. they
had to select one of the two hypothetical treat-
ment options presented). In pre-tests, no partic-
ipants indicated that they would refuse therapy
with any of the options presented. Nevertheless,
there are many individual, personal factors and
circumstances that can influence actual treatment
decisions that are not accounted for in our study.
For example, cost is sometimes cited as a bar-
rier to treatment in the US, but not in the other
surveyed countries. A number of other possible
attributes were considered for inclusion in the study,
including jaundice and the chance of a rapid vi-
rologic response (RVR) at week 4. In pre-tests,
patients ignored jaundice and RVRwhen making
their choices and consistently confirmed the lack
of importance of those features when queried.
Eliminating attributes that do not materially
affect decision making reduces the cognitive burden
on participants. If the cognitive burden is too
high, respondents may employ simplifying heu-
ristics to facilitate the task of choosing among the
alternatives presented. A common strategy used
to simplify choice tasks is to focus on a single
attribute, whereby the respondent always chooses
the alternative with the best or most attractive
level of the attribute. When participants domi-
nate on a single attribute, their preferences be-
tween attributes cannot be observed, obviating
the purpose of the survey. In survey pre-testing,
patients generally had strong preferences for SVR,
but they were willing to trade improvements in
SVR to offset treatment risks and other, neg-
atively viewed treatment attributes. Patients were
not observed having difficulty completing the
choice tasks in pre-tests of the final instrument,
nor was the use of any simplifying decision-making
strategies detected. In the final survey, fewer than
3% of respondents dominated on an attribute,
and no more than two respondents dominated on
any particular attribute. The success of the pre-
tests and the lack of dominance in the final survey
are evidence that cognitive burden was not an
issue in this study.
A second limitation of conjoint studies con-
cerns the absolute values and ranges for the attrib-
ute levels in the study. Thus, the preference weight
results are valid and should be interpreted only
over the specific ranges of risk and other attribute
levels presented in the survey. The ranges for the
risk attribute levels in the present study encom-
passed the expected clinical prevalence but also
included levels strong enough to induce trade-offs
between attributes. If the levels were set too low
or too high, we would never observe any trade-offs
between anemia risk and the other treatment at-
tributes. One purpose of the pre-test interviews was
to inform the range and absolute values of the levels.
Random-parameters logit was used to account
for unobserved heterogeneity in responses across
respondents. Understanding heterogeneity in
choice models is particularly difficult because the
models estimate the effect of attribute levels on
choice. Attribute levels change across alternatives,
but individual-specific characteristics do not. There-
fore, individual-specific attributes drop out of the
estimator unless they are interacted with the at-
tribute levels. Estimation of an interaction model
would have required too many degrees of free-
dom to be supported by our sample size. Similarly,
the study was not powered to conduct a split-
sample analysis (i.e. by country). A third general
approach to testing for heterogeneity, latent class
analysis, was conducted and identified three
preference groups. Continuous age was the only
observed, statistically significant predictor of class.
The respondents’ country was not a statistically
significant predictor of class. Because we found
no signal to indicate that a respondent’s country
or any other demographic characteristic meas-
ured in the study, with the possible exception of
age, explained differences in preferences, prefer-
ence heterogeneity was treated as unobserved.
The relatively low prevalence of chronic HCV
infection among the general US population poses
challenges for the conduct of quantitative, patient-
reported preference studies. Online surveys, when
conducted using established patient panels, allow
access to large numbers of patients in a relatively
short time period, making important information
about patients’ preferences and decision making
available in a timelymanner. Internet-based research
has been used increasingly to quantify preferences
for attributes of health, healthcare, and health-
care policy.[11,43-45]
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While the demographic characteristics of par-
ticipants with internet access may differ from those
of individuals without such access, the psychometric
properties of web-based versus paper-and-pencil
surveys are comparable.[46] A full comparison of
patient demographics between the overall HCV-
infected populations in each of the five survey
countries and the study sample was not possible,
but data from the National Health and Nutrition
Examination Survey (NHANES) indicate that
the mean age of individuals infected with HCV in
the US, including those with undiagnosed infec-
tion, is approximately 47 years, with 62% of in-
fections occurring in males.[47] Thus, participants
in this survey were slightly younger and less likely
to be male than the average HCV-infected in-
dividual in the US.
Conclusion
Results from the present study suggest that
patients with chronic HCV infection place a very
high premium on SVR and are willing to accept
longer treatment duration for sufficient improve-
ment in the chance of a successful treatment out-
come. With new therapies for HCV on the very
near horizon, an understanding of how patients
view the benefits and risks of treatment is necessary
for treatment planning at both the patient and the
public health levels. Additionally, patient prefer-
ences may inform the development of future
HCV treatments.
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